Case report: Kaposi hemangioendothelioma of the right upper limb with the Kasabach–Merritt phenomenon: A potentially lethal diagnostic challenge

Levin Belani¹, Jamari Sapuan¹, Shalimar Abdullah¹, Erica Yee Hing², C-Khai Loh³ and Hamidah Alias³*

¹Department of Orthopaedic and Traumatology, UKM Medical Centre, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. ²Department of Radiology, UKM Medical Centre, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. ³Pediatric Hematology and Oncology Unit, Department of Pediatrics, UKM Medical Centre, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia

Kaposi hemangioendothelioma (KHE) is a rare vascular neoplasm that presents usually within the first year of life. Because of its rarity and complexity, there is often a delay in diagnosis. KHE could be associated with a life-threatening consumptive coagulopathy named the Kasabach–Merritt phenomenon (KMP). Here, we present the case of a 2-month-old girl who presented with progressive redness and swelling of her right upper limb over 6 weeks. Multiple health practitioners misdiagnosed her condition as an insect bite, cellulitis, and necrotizing fasciitis and gave treatment accordingly, which proved futile. A full blood count revealed bicytopenia of anemia and thrombocytopenia, a normal coagulation cascade, low fibrinogen, and raised D-Dimer levels. The imaging was suggestive of a high-flow vascular tumor likely to be a KHE. Subsequently, she was started on single-agent oral sirolimus with a dose increment to achieve satisfactory therapeutic levels and was treated for 1 year. She successfully completed the treatment regimen and had only transient hypertriglyceridemia, which resolved upon the completion of treatment. Currently, she is in remission 3 years after treatment. Keeping her case as an example, we would like to highlight the potentially lethal misdiagnosis of KHE with KMP, the importance of an early diagnosis of this condition, and the successful treatment outcome with single-agent sirolimus.

KEYWORDS
kaposi hemangioendothelioma, Kasabach–Merritt, upper limb, sirolimus, treatment outcome
Introduction

Kaposi hemangioendothelioma (KHE) is a rare vascular neoplasm diagnosed during infancy or early childhood with a prevalence and incidence of 0.91 and 0.071 per 100,000 children, respectively (1). Men have a slight predominance over women, as reported in two large retrospective studies (2, 3). KHE is mostly evident (90%) within the first year of life (4). The etiology of this disease remains unknown, and in most cases, KHE occurs insidiously (5). The Kasabach–Merritt phenomenon (KMP) is a life-threatening coagulopathy occurring in 70% of KHE cases (1). In view of the rarity of KHE with KMP, delay in diagnosis may lead to morbidity and mortality of up to 30% mostly due to life-threatening hemorrhage, cardiac failure, and local invasion of the neoplasm (6).

Case presentation

A 2-month-old girl presented with a 6-week history of progressive swelling over the right forearm. She was delivered at term via emergency lower-section cesarean section with a birth weight of 2.92 kg. Antenatally, the mother had gestational diabetes mellitus and had a history of threatened preterm labor. The intrapartum and postpartum periods were uneventful. At 2 weeks old, a small erythema was noted at the lateral right forearm that progressed to involve the entire right forearm, with progressive swelling in the next 3 weeks. There was no history of trauma or fall. There was no family history of malignancy. The child remained active, was feeding well, was not fretful, and was afebrile. There was no limitation to her range of motion, nor did she cry upon handling.

At 1 week of illness, her mother brought her to a general practitioner, and she was treated symptomatically for urticaria, presumably caused by an insect bite. However, as the redness in her upper limb persisted and the swelling enlarged, she was brought to another medical practitioner and was then admitted to a hospital a week later and treated for cellulitis of the right upper limb with intravenous antibiotics. The infant received packed red blood cells, platelet, and sirolimus was commenced with an initial dosage of 0.2 mg BD (0.8 mg/m²/dose). According to the institutional policy, sirolimus can be used only for children aged 2 years and above; however, ethical approval was obtained for the drug to be used in this infant. After 14 days of sirolimus treatment, a reduction in redness and swelling of the right upper limb was observed and the platelet normalized to 123 x 10⁹/L. The patient was discharged home after 1 week of admission, and oral sirolimus of the same dose was continued for 4 months before the dose was increased to 0.4 mg BD, 0.6 mg BD, and then 0.8 mg BD up to a total duration of 1 year. There was an issue related to compliance with sirolimus during months 3 and 4 of the treatment. During treatment, the serum sirolimus levels were closely monitored to achieve a trough level of between 10 and 15 ng/ml. The serum levels were checked weekly during the first month of treatment, then biweekly for the subsequent month, and then monthly. After a stable dose was achieved, therapeutic drug monitoring was performed every 3 months. A prophylaxis for pneumocystis pneumonia, trimethoprim/sulfamethoxazole, was started concomitantly until the treatment was completed. An ultrasound-guided biopsy was performed under sedation 2 months after treatment started with a normal coagulation profile, and the histopathological examination showed a proliferation of multiple scattered, small, round, and some
slit-like vascular channels within the deep dermis and subcutaneous fat that are lined by bland endothelial cells. Some of the cells appeared to form a glomeruloid structure. The endothelial cells were positive for CD31 and CD34, which were suggestive of a vascular lesion favoring KHE.

She was also followed up regularly following the treatment protocol to monitor the full blood count, renal profile, liver function, and fasting serum lipids. She had transient hypertriglyceridemia, which resolved after the treatment was completed. A repeat MRI after 6 months of treatment revealed a complete resolution of the lesion (Figures 2C,D); however, clinically, there was some residual skin discoloration. After the completion of the dosage of 1 year of oral sirolimus, the right upper limb swelling and discoloration resolved completely (Figure 3A). Currently, at the age of 3 years, she remains in remission (Figure 3B). Her parents are highly satisfied with the treatment outcome and are compliant with the follow-up regime.

Discussion

A right upper limb redness and swelling in infants is often diagnosed as cellulitis, necrotizing fasciitis, hematoma, or a vascular tumor. The baby girl who was referred to our center initially presented herself to multiple health practitioners, who misdiagnosed her condition and delayed the definitive diagnosis of KHE with KMP, which could potentially be fatal. The delay in diagnosis could be explained by the rarity of the disease condition, a lack of experience in clinical diagnosis, the deep location of the tumor (mediastinum or retroperitoneum), and coagulopathy, making biopsy challenging (7).

The clinical diagnosis of KHE requires a thorough history and examination, blood investigations, imaging, and biopsy. KHE presentation could be heterogenous and variable, thus providing a diagnostic challenge. The spectrum of presentation could vary from cutaneous lesions with variable appearances to deep masses without any cutaneous signs. Patients with KMP and without KMP could also be distinguished through examination (5). KHE presents commonly with a single soft tissue mass with cutaneous findings, which range from an erythematous papule or nodule to a firm purplish tumor (5). These lesions are usually painful, hot to the touch, swollen, and purpuric in patients with KMP (5). In this case, the initial presentation to the orthopedic team did not lead to the diagnosis of KHE just through clinical history and examination. Differential diagnoses of such lesions include infantile hemangioma, congenital hemangiomias that include rapidly involuting congenital hemangioma (RICH), and kaposiform lymphangiomatosis (5, 8, 9).

Hematological investigations reveal thrombocytopenia and consumptive coagulopathy in cases suggestive of KMP. KMP is a rare, life-threatening condition that occurs in 70% of patients diagnosed with KHE (10). Thrombocytopenia in KMP is usually severe, with a median platelet count of $21 \times 10^9/L$ (11). In this case, the infant presented with
thrombocytopenia of 8 × 10^9/L, which could likely cause severe bleeding within the compartment of her right upper limb, leading to anemia and consumptive coagulopathy. The postulation behind the thrombocytopenia has been attributed to platelet trapping within the lesion due to extracellular damage or alteration in KHE, leading to activation and aggregation of platelets, which results in subsequent consumptive coagulopathy (5). In KHE, the thrombi in the microvasculature cause vessel occlusion and prevent normal blood flow. This could lead to increased shear stress and induce increased platelet activation. This process, in turn, causes further platelet trapping and activation during the active phase of KHE (5). Given the life-threatening nature of thrombocytopenia and consumptive coagulopathy, we treated the patient with a regime of blood products to stabilize her condition upon admission as she bled from the peripheral line insertion site. The utilization of blood product support is crucial during active bleeding despite a potential worsening of KMP, with platelet transfusion aggravating platelet aggregation. In cases of active bleeding, severe coagulopathy, and/or thrombocytopenia, fresh frozen plasma and/or cryoprecipitate can be used in the treatment of KMP (12).

Imaging modalities such as ultrasound and MRI are helpful to aid the diagnosis of KHE. Ultrasound is recommended in superficial and small lesions, while MRI is helpful to diagnose deep infiltrating KHE, which may not be apparent on physical examination (13). The features suggestive of KHE on ultrasound and MRI were discussed above. A biopsy of the lesion remains the gold standard in the diagnosis of KHE and it should be performed when the patient’s condition allows it and when it is considered safe (5). The infant underwent a percutaneous ultrasound doppler–guided biopsy, which was a closed biopsy under sedation performed by an experienced pediatric radiologist. A confirmatory diagnosis was crucial to differentiate KHE from other vascular abnormalities and could predict the long-term outcome and benefits of the subject therapy. The hallmark features of KHE are the infiltrating, defined, rounded, and confluent nodules that are composed of spindle endothelial cells. These cells form a malformed lymphatic channel and slit-like vascular lumen. The lumen contents include erythrocytes, platelet thrombi, eosinophilic hyaline bodies, and hemosiderin deposits (5). Immunohistochemical staining of KHE includes positivity for CD31 and CD34, which are the vascular endothelial markers that were present in this case (14).

The heterogeneity and the presence of disease-related comorbidities make the management of KHE challenging. The
optimum treatment for KHE with KMP has not been established, and to date, there are no medications approved by the FDA for this condition. Ideal therapies for KHE with KMP would target cellular pathways important in abnormal vascular proliferation and growth (2). A treatment used previously includes systemic pharmacotherapy such as vincristine, corticosteroids, sirolimus, topical sirolimus or tacrolimus, ticlopidine, and aspirin (5). Multiple treatment regimens have been used for KHE with KMP with varying success, and the most recent randomized clinical trials reported encouraging results of using combination therapy with sirolimus plus prednisolone (5, 12, 15). Sirolimus, an inhibitor of the mammalian target of rapamycin (mTor), has been demonstrated to show satisfactory efficacy as oral administration in the treatment of KHE (16–19). There are a number of published reports on the use of sirolimus monotherapy in KHE with KMP, and it appears to be effective and safe in patients with life-threatening vascular anomalies (18, 20). The pathophysiology of KHE involves dysregulation of both angiogenesis and lymphangiogenesis. The classic spindle cell morphology found in KHE is thought to have a significant lymphatic component since these lesions stain with lymphatic endothelial markers D2-40 (podoplanin) and Prox-1 (21, 22). Sirolimus is effective on the lymphangiogenesis pathway, in which ligand-binding-induced signaling through VEGFR-3 on the surface of the lymphatic endothelium results in the activation of the PI3K/Akt/mTOR pathway (23, 24). The duration of treatment with sirolimus for KHE has been reported to be variable, and in a case series, it was reported that 12 months of treatment with sirolimus was associated with no disease recurrence. However, more studies are needed to investigate the most feasible duration of therapy required. Our experience suggests that sirolimus monotherapy of 12 months is a reasonable treatment for an infant with KHE with KMP, as it showed a good resolution of the lesion over the right upper limb and coagulopathy. We also monitored the patient for possible adverse effects of sirolimus including bone marrow suppression, metabolic derangements of hypercholesterolemia and hypertriglyceridemia, gastrointestinal side effects, as well as the rare side effect of pneumonia (14, 25). The patient tolerated the oral sirolimus well with only transient hypertriglyceridemia. The patient has been on a multidisciplinary team follow-up for 3 years now and has remained in continuous remission.

**Conclusion**

Kaposi hemangioendothelioma with KMP is a rare vascular neoplasm that can pose a diagnostic challenge to many treating physicians. A delay in diagnosis may lead to a potentially devastating outcome for the patient. Early diagnosis and initiation of treatment promise a good outcome.

**Data availability statement**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

**Ethics statement**

Ethical review and approval were not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the patient’s next of kin for the publication of any potentially identifiable images or data included in this article.

**Author contributions**

LB, JS, SA, C-KL, and HA were responsible for the clinical management of the patient. EYH was responsible for the imaging of the patient. LB acquired the clinical data and drafted the initial manuscript. HA reviewed the intellectual contents of the manuscript and made substantial modifications during revision. All authors contributed to the article and approved the submitted version.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

1. Croteau SE, Liang MG, Kozakewich HP, Alomari AI, Fishman SJ, Mulliken JB, et al. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach–Merritt phenomenon in 107 referrals. J Pediatr. (2013) 162(1):142–7. doi: 10.1016/j.jpeds.2012.06.044

2. Adams DM, Brandão LR, Peterman CM, Gupta A, Patel M, Fishman S, et al. Vascular anomaly cases for the pediatric hematologist oncologist—an interdisciplinary review. Pediatr Blood Cancer. (2018) 65:e26716. doi: 10.1002/pbc.26716

3. Mahajan P, Margolin J, Iacobas I. Kasabach–Merritt phenomenon: classic presentation and management options. Clin Med Insights Blood Disord. (2017) 10. doi: 10.1177/1179543X17699849. [Epub ahead of print]

4. Ji Y, Yang K, Peng S, Chen S, Xiang B, Xu Z, et al. Kaposiform hemangioendothelioma: clinical features, complications and risk factors for Kasabach–Merritt phenomenon. Br J Dermatol. (2018) 179(2):457–63. doi: 10.1111/bjd.16601

5. Ji Y, Chen S, Yang K, Xia C, Li L. Kaposiform hemangioendothelioma: current knowledge and future perspectives. Orphanet J Rare Dis. (2020) 15(1):1–16. doi: 10.1186/s13023-020-1320-1

6. Lewis D, Vaadya R, Kasabach–Merritt syndrome. Treasure Island, FL: StatPearls (2022). [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK519053/ (Accessed July 3, 2022).

7. Vivas-Colmenares G, Ramirez-Villar G, Bernabeu-Wittel J, Matute de Cardenas J, Fernandez-Pineda I. The importance of early diagnosis and treatment of kaposiform hemangioendothelioma complicated by Kasabach–Merritt phenomenon. Dermatol Pract Concept. (2012) 5(1):91–3. doi: 10.5826/dpc501a18

8. Baezga E, Cordisco M, Garzon M, Lee M, Alomar A, Blei F. Rapidly involving congenital hemangioendothelioma associated with transient thrombocytopenia and coagulopathy: a case series. Br J Dermatol. (2008) 158:1363–70. doi: 10.1111/j.1365-2133.2008.08546.x

9. Almas H, Abdul Rashid AH, Lau SCD, Loh CK, Sapuan J, Ibrahim S, et al. Early surgery is feasible for a very large congenital infantile fibrosarcoma associated with life threatening coagulopathy: a case report and literature review. Front Pediatr. (2019) 7:529. doi: 10.3389/fped.2019.00529

10. White JR, McCormick A. Kasabach–Merritt phenomenon in kaposiform hemangioendothelioma: red flags in neonatal vascular lesions. Pediatr Rev. (2021) 42(3, Meeting Abstract):871–871. doi: 10.1542/peds.1473.MA9.A871

11. Ji Y, Yang K, Chen S, Peng S, Lu G, Liu X. Musculoskeletal complication in kaposiform hemangioendothelioma without Kasabach–Merritt phenomenon: clinical characteristics and management. Cancer Manag Res. (2018) 10. doi: 10.3325/10.1111/1346-8138.15025

12. Ji Y, Chen S, Xiang B, Liu X, Yao W, et al. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: a multicenter retrospective study. Int J Cancer. (2017) 141(4):848–55. doi: 10.1002/ijc.30775

13. Gong X, Ying H, Zhang Z, Wang L, Li J, Ding A, et al. Ultrasonography and magnetic resonance imaging features of kaposiform hemangioendothelioma and tufted angiomaly. J Dermatol. (2019) 46(10):855–42. doi: 10.1111/1346-8138.15025

14. Chundrger Q, Tariq MU, Abdul-Ghafar J, Ahmed A, Din NU. Kaposiform hemangioendothelioma: clinicopathological characteristics of 8 cases of a rare vascular tumor and review of literature. Diagn Pathol. (2021) 16(1):1–8. doi: 10.1186/s13023-021-01108-9

15. Ji Y, Chen S, Zhou J, Yang K, Zhang X, Xiang B, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial. Blood. (2017) 131(13):1619–30. doi: 10.1182/blood.2017104027

16. Cabrera TB, Speer AL, Greaves MR, Goff DA, Menon NM, Reynolds EW. Sirolimus for kaposiform hemangioendothelioma and Kasabach–Merritt phenomenon in a neonate. AJP Rep. (2020) 10(4):E390–4. doi: 10.1055/s-0040-1718901

17. Blatt J, Stavas J, Moats-Staats B, Woolesy J, Morrell DS. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer. (2010) 55(7):1396–8. doi: 10.1002/pbc.22766

18. Hammill AM, Wentzl M, Gupta A, Nelson S, Lucky A, Elluru R, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. (2011) 57(6):1018–24. doi: 10.1002/pbc.23124

19. Kui L, Wang Z, Yao W, Deng K, Xiao XJ. Sirolimus, a promising treatment for refractory kaposiform hemangioendothelioma. Cancer Res Clin Oncol. (2014) 140(3):471–6. doi: 10.1007/s00432-013-1549-3

20. Schmid J, Klenk AK, Sparber-Sauer M, Kocsielniak E, Maxwell R, Haberle B. Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options. World J Pediatr. (2018) 14(4):322–9. doi: 10.1007/s12519-018-0171-5

21. Develenko LV, Perez-Atayde AR, Mulliken JB, Liang MG, Archibald TH, Kozakewich HP. D 2-40 immunohistochemical analysis of pediatric vascular tumors reveals positivity in kaposiform hemangioendothelioma. Mod Pathol. (2005) 18:1454–60. doi: 10.1038/modpathol.3800444

22. Le Hua AR, Jokinen CH, Ruben BP, Mihm MC, Weiss SW, North PE, et al. Expression of PROX1, lymphatic endothelial nuclear transcription factor, in kaposiform hemangioendothelioma and tufted angioma. Am J Surg Pathol. (2010) 34:1563–73. doi: 10.1097/PAS.0b013e31816076f

23. Makenine T, Veikkola T, Mustoji S, Karpanen T, Catimel B, Nice EC, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. (2001) 20:4762–73. doi: 10.1093/emboj/20.17.4762

24. Salameh A, Galvagni F, Bardelli M, Busolino F, Oliviero S. Direct recruitment of CRK and GHR2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. Blood. (2005) 106:3423–31. doi: 10.1182/blood-2005-04-1388

25. Wang Y, Kong J, Sun B, Cui J, Shen W. Sirolimus for kaposiform hemangioendothelioma with Kasabach–Merritt phenomenon in two infants. J Craniofac Surg. (2020) 31(4):1074–7. doi: 10.1097/SCS.0000000000006301